• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • Bullous Pemphigoid Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PolandChange country/region
Dermatology

ADVENT at WCPD 2025

The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
Past event
8April2025
Location
Centro de Convenciones de la Ciudad de Buenos Aires
Buenos Aires Argentina

Symposium Details

April 10

How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

Location

Centro de Convenciones de la Ciudad de Buenos Aires
Buenos Aires Argentina
Tags
symposium
MAT-GLB-2500297 - 1.0 - 03/2025

Related resources

On the Surface: Restoring the Skin Barrier in Patients With AD
Dermatology
17 min
expert video

On the Surface: Restoring the Skin Barrier in Patients With AD

Charting the Future: Preventing the Atopic March
Dermatology
10 min
expert video

Charting the Future: Preventing the Atopic March

KOL Video Interview – Dr Paula Luna
Dermatology
2 min
expert video

KOL Video Interview – Dr Paula Luna

Charting the Future: Preventing the Atopic March
Dermatology
2 min
expert video

Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March
Dermatology
3 min
expert video

Charting the Future: Preventing the Atopic March

KOL Video Interview – Dr Amy Paller
Dermatology
2 min
expert video

KOL Video Interview – Dr Amy Paller